Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Triple-negative breast cancers have inherent defects in DNA repair, making this cancer a rational target for therapy based on poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition. METHODS: We conducted an open-label, phase 2 study to compare the efficacy and safety of gemcitabine and carboplatin with or without iniparib, a small molecule with PARP-inhibitory activity, in patients with metastatic triple-negative breast cancer. A total of 123 patients were randomly assigned to receive gemcitabine (1000 mg per square meter of body-surface area) and carboplatin (at a dose equivalent to an area under the concentration-time curve of 2) on days 1 and 8--with or without iniparib (at a dose of 5.6 mg per kilogram of body weight) on days 1, 4, 8, and 11--every 21 days. Primary end points were the rate of clinical benefit (i.e., the rate of objective response [complete or partial response] plus the rate of stable disease for ≥6 months) and safety. Additional end points included the rate of objective response, progression-free survival, and overall survival. RESULTS: The addition of iniparib to gemcitabine and carboplatin improved the rate of clinical benefit from 34% to 56% (P=0.01) and the rate of overall response from 32% to 52% (P=0.02). The addition of iniparib also prolonged the median progression-free survival from 3.6 months to 5.9 months (hazard ratio for progression, 0.59; P=0.01) and the median overall survival from 7.7 months to 12.3 months (hazard ratio for death, 0.57; P=0.01). The most frequent grade 3 or 4 adverse events in either treatment group included neutropenia, thrombocytopenia, anemia, fatigue or asthenia, leukopenia, and increased alanine aminotransferase level. No significant difference was seen between the two groups in the rate of adverse events. CONCLUSIONS: The addition of iniparib to chemotherapy improved the clinical benefit and survival of patients with metastatic triple-negative breast cancer without significantly increased toxic effects. On the basis of these results, a phase 3 trial adequately powered to evaluate overall survival and progression-free survival is being conducted. (Funded by BiPar Sciences [now owned by Sanofi-Aventis]; ClinicalTrials.gov number, NCT00540358.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The oncology literature has indicated that positive phase II data are not necessarily replicated in the phase III setting”
In the citing paper
“Furthermore, ongoing clinical trials for metastatic TNBC are including platinum agents in their treatment regimens (4, 36–38).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [36]
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
Cited by
Items 501–600 of 876
Massard, C., Cassier, P. A., Azaro, A., Anderson, B., Yuen, E., Yu, D., Oakley, G. J., Benhadji, K. A., & Pant, S. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04461-z · Cited by 15
Banz‐Jansen, C., Heinrichs, A., Hedderich, M., Waldmann, A., Wedel, B., Mebes, I., Diedrich, K., Rody, A., & Fischer, D. (2013) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-013-2738-7 · Cited by 15
Novel Targeted Agents for the Treatment of Advanced Breast Cancer
Vega, M., Diaz-Canton, E. A., & Álvarez, R. H. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.45 · Cited by 15
Prospective Evaluation of Universal BRCA Testing for Women With Triple-Negative Breast Cancer
Emborgo, T. S., Saporito, D., Muse, K. I., Gutierrez‐Barrera, A. M., Litton, J. K., Lu, K. H., & Arun, B. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa002 · Cited by 15
Systemic treatment of early breast cancer—a biological perspective
Greenberg, S., Stopeck, A., & Rugo, H. S. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.21842 · Cited by 14
Laimito, K. R., Gámez‐Pozo, A., Sepúlveda-Sánchez, J. M., Manso, L., López‐Vacas, R., Pascual, T., Vara, J. Á. F., & Ciruelos, E. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.632 · Cited by 14
Promising therapeutic options in triple-negative breast cancer.
Bilici, A. E., Arslan, Ç., & Altundağ, K. (2012) · PubMed · Cited by 14
Caputo, A., Vipparthi, K., Bazeley, P. S., Downs, E., McIntire, P. J., Duckworth, L. A., Ni, Y., Hu, B., Keri, R. A., & Karaayvaz, M. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-23-0489 · Cited by 14
Characteristics and therapy of premenopausal patients with early-onset breast cancer in Germany
Banz‐Jansen, C., Heinrichs, A., Hedderich, M., Waldmann, A., Dittmer, C., Wedel, B., Mebes, I., Diedrich, K., & Fischer, D. (2012) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-012-2291-9 · Cited by 14
Emerging PARP inhibitors for treating breast cancer
Robert, M., Patsouris, A., Frenel, J., Gourmelon, C., Augereau, P., & Campone, M. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1527900 · Cited by 14
Target Discovery Using Thermal Proteome Profiling
Sridharan, S., Günthner, I., Becher, I., Savitski, M. M., & Bantscheff, M. (2019) · Wiley eBooks · doi:10.1002/9781118970195.ch11 · Cited by 14
Yang, R., Shi, Y., Han, X., & Liu, S. (2021) · Oncology Research and Treatment · doi:10.1159/000515353 · Cited by 14
Dranitsaris, G., Glück, S., Faria, C., Cox, D., & Rugo, H. S. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.10.023 · Cited by 14
Warrener, P., Kim, S., Williams, S. M. G., Biery, M. C., Gordon, M. L., Toniatti, C., Cleary, M. A., Linsley, P. S., & Carleton, M. O. (2012) · APOPTOSIS · doi:10.1007/s10495-012-0707-4 · Cited by 14
Sun, B., Liu, Y., Liu, T., Zhao, X., Wang, X., Li, Y., Meng, J., Gu, Q., Liu, F., Dong, X., et al. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s93015 · Cited by 14
PARP inhibition: A promising therapeutic target in ovarian cancer.
Musella, A., Marchetti, C., Gasparri, M. L., Salerno, L., Casorelli, A., Domenici, L., Imperiale, L., Ruscito, I., Halim, T. A., Palaia, I., et al. (2015) · Cellular and Molecular Biology · doi:10.14715/cmb/2015.61.6.8 · Cited by 14
Effects of TPX2 gene on radiotherapy sensitization in breast cancer stem cells
Huang, C.-Y., Han, Z., & Wu, D. (2017) · Oncology Letters · doi:10.3892/ol.2017.6277 · Cited by 13
Advances in Medical Management of Early Stage and Advanced Breast Cancer: 2015
Witherby, S. M., Rizack, T., Sakr, B. J., Legare, R. D., & Sikov, W. M. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2015.09.005 · Cited by 13
Jhan, J.-R., & Andrechek, E. R. (2017) · Oncogene · doi:10.1038/onc.2016.503 · Cited by 13
Tian, Q., Du, P., Li, S., Bai, Z., Yang, Y., & Zeng, J. (2017) · Medicine · doi:10.1097/md.0000000000008389 · Cited by 13
Stem Cells, Cell Differentiation, and Cancer
Dalerba, P. D., Diehn, M., Weissman, I. L., & Clarke, M. F. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00007-4 · Cited by 13
Blakeley, J. O., Grossman, S. A., Mikkelsen, T., Rosenfeld, M. R., Peereboom, D. M., Nabors, B., Chi, A. S., Emmons, G., Ribas, I. G., Supko, J. G., et al. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1876-0 · Cited by 14
Walker, M. S., Masaquel, A. S., Kerr, J., Lalla, D., Abidoye, O. O., Houts, A. C., & Schwartzberg, L. S. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2892-z · Cited by 13
Penson, R. T., Ambrosio, A. J., Whalen, C. A., Krasner, C. N., Konstantinopoulos, P. A., Bradley, C., Matulonis, U. A., & Birrer, M. J. (2023) · The Oncologist · doi:10.1093/oncolo/oyac275 · Cited by 12
Self-citationConte, P., & Guarneri, V. (2012) · Clinical Breast Cancer · doi:10.1016/j.clbc.2012.03.005 · Cited by 12
Parp Inhibitor Treatment of Advanced Breast Cancer Beyond the BRCA -Mutated Type: A Meta-Analysis
Yan, F., Jiang, Q., He, M., & Shen, P. (2021) · Future Oncology · doi:10.2217/fon-2020-1175 · Cited by 12
Voies de réparation de l’ADN et cancers bronchiques non à petites cellules : perspectives cliniques
Olaussen, K. A., Planchard, D., Adam, J., & Soria, J. (2011) · Bulletin du Cancer · doi:10.1684/bdc.2011.1327 · Cited by 12
Effect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: A meta-analysis
Tian, M., Zhong, Y., Zhou, F., Xie, C., Zhou, Y., & Liao, Z. (2015) · Oncology Letters · doi:10.3892/ol.2015.3072 · Cited by 12
Population and Target Considerations for Triple-Negative Breast Cancer Clinical Trials
Hyslop, T., Michael, Y., Avery, T. P., & Rui, H. (2013) · Biomarkers in Medicine · doi:10.2217/bmm.12.114 · Cited by 12
Potential options for managing LOX+ ER− breast cancer patients
Han, Y. K., Lian, S., Cui, X., Meng, K., Győrffy, B., Jin, T., & Huang, D. (2016) · Oncotarget · doi:10.18632/oncotarget.9073 · Cited by 12
Michieli, P., Basilico, C., & Pennacchietti, S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1534 · Cited by 12
García-Sáenz, J. Á., Rodríguez-Lescure, Á., Jurado, J. C., Albanell, J., Alba, E., & Llombart‐Cussac, A. (2025) · Targeted Oncology · doi:10.1007/s11523-024-01125-1 · Cited by 11
Treatment Progress in Triple Negative Breast Cancer
(2022) · European Journal of Gynaecological Oncology · doi:10.31083/j.ejgo4302040 · Cited by 11
Treatment for triple-negative breast cancer
Shi, X., & Wang, L. (2012) · The Chinese-German Journal of Clinical Oncology · doi:10.1007/s10330-012-1023-8 · Cited by 11
Hadidi, S. A., Aburahma, A., Badami, S., & Upadhaya, S. (2018) · Oncology Research and Treatment · doi:10.1159/000486418 · Cited by 11
UK Guidance Document: Treatment of Metastatic Breast Cancer
Coleman, R. E., Bertelli, G., Beaumont, T., Kunkler, I. H., Miles, D., Simmonds, P. D., Jones, A. L., & Smith, I. E. (2011) · Clinical Oncology · doi:10.1016/j.clon.2011.10.004 · Cited by 11
XAV939-Mediated ARTD Activity Inhibition in Human MB Cell Lines
Renna, C., Salaroli, R., Cocchi, C., & Cenacchi, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124149 · Cited by 11
Triple-negative breast cancer: New therapeutic options via signalling transduction cascades
Andergassen, U., Kölbl, A. C., Mumm, J., Mahner, S., & Jeschke, U. (2017) · Oncology Reports · doi:10.3892/or.2017.5512 · Cited by 11
Actualización del cáncer de mama en atención primaria (IV/V)
Álvarez-Hernández, C., Brusint, B., Vich-Pérez, P., Diaz-Garcia, N., Cuadrado-Rouco, C., & Hernández-García, M. (2014) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2014.03.004 · Cited by 11
Shekh, K., Khan, S., Jena, G., Kansara, B. R., & Kushwaha, S. (2014) · Toxicology Mechanisms and Methods · doi:10.3109/15376516.2014.898355 · Cited by 11
Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy
Kluzek, K., Białkowska, A., Koczorowska, A. M., & Zdzienicka, M. Z. (2012) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/17322693.1000548 · Cited by 11
Osborne, C., Challagalla, J. D., Eisenbeis, C. F., Holmes, F. A., Neubauer, M., Koutrelakos, N., Taboada, C. A., Vukelja, S. J., Wilks, S. T., Allison, M. A., et al. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2017.07.002 · Cited by 11
Self-citationThomssen, C., Scharl, A. J., & Harbeck, N. (2011) · Breast Care · doi:10.1159/000331459 · Cited by 11
The Changing Landscape of Breast Cancer: How Biology Drives Therapy
Friend, S., & Royce, M. (2016) · Medicines · doi:10.3390/medicines3010002 · Cited by 10
Li, C., Hao, M., Fang, Z., Ding, J., Duan, S., Yi, F., Wei, Y., & Zhang, W. (2023) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-023-04506-x · Cited by 10
Mutter, R. W., & Powell, S. N. (2011) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2011.06.011 · Cited by 10
Narayanan, S., Teng, Q., Koya, J., Wang, J., Assaraf, Y. G., Charles, R. A., & Zhe-Sheng, C. (2019) · Journal of Molecular and Clinical Medicine · doi:10.31083/j.jmcm.2019.03.0303 · Cited by 10
Jian, D., Li, X., Dai, N., Liang, D., Zhang, G., Mao, C., Wang, D., Song, G., Li, M., & Luo, H. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/6048017 · Cited by 10
Optimal Management of Ewing Sarcoma Family of Tumors: Recent Developments in Systemic Therapy
Owens, C., Abbott, L. S., & Gupta, A. A. (2013) · Pediatric Drugs · doi:10.1007/s40272-013-0037-1 · Cited by 10
How do I Treat “Triple-Negative” Disease
Vaklavas, C., & Forero, A. (2011) · Current Treatment Options in Oncology · doi:10.1007/s11864-011-0168-y · Cited by 10
Prevention of ER-negative breast cancer: where do we stand?
Cazzaniga, M., & Bonanni, B. (2011) · European Journal of Cancer Prevention · doi:10.1097/cej.0b013e32834c9c26 · Cited by 10
Quesada, A., O’Valle, F., Montoro-Molina, S., Gómez‐Morales, M., Molina, M. C., González, J. F., de Gracia, M. C., Osuna, A., Vargas, F., & Wangensteen, R. (2018) · Bioscience Reports · doi:10.1042/bsr20171313 · Cited by 10
Song, Z., Wang, Y., Xia, Q., Yu, Z., Zhao, L., Wu, H., Sun, M., Chai, Z., Hou, P. K., Geng, X., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.9398 · Cited by 10
Kandula (2013) · World Journal of Oncology · doi:10.4021/wjon681e · Cited by 10
PARP inhibitors – theoretical basis and clinical application
Dębska-Szmich, S., Kubicka, J., Czyżykowski, R. Ł., Habib, M., & Potemski, P. (2012) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/17322693.999033 · Cited by 10
Somatic mutations in the BRCA1 gene in Chinese women with sporadic breast cancer
Zhang, M., Xu, Y., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., & Xie, Y. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1887-2 · Cited by 10
The impact of germline mutations on targeted therapy
Smith, S. A., French, T., & Hollingsworth, S. J. (2013) · The Journal of Pathology · doi:10.1002/path.4273 · Cited by 10
Targeting Breast Cancer: The Familiar, the Emerging, and the Uncharted Territories
Aliabadi, H. M., Manda, A., Sidgal, R., & Chung, C. (2023) · Biomolecules · doi:10.3390/biom13091306 · Cited by 9
Developing combination therapies with biologics in triple-negative breast cancer
Gaudio, G., Martino, E., Pellizzari, G., Cavallone, M., Castellano, G., Omar, A. A., Katselashvili, L., Trapani, D., & Curigliano, G. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2408756 · Cited by 9
Chang, X.-F., Ren, X.-L., Yang, J.-Q., Jian-jun, S., Bai, J., Cui, M., & Dong, W. (2021) · The Breast · doi:10.1016/j.breast.2021.05.009 · Cited by 9
Orlando, L., Schiavone, P., Fedele, P., Calvani, N., Nacci, A., Cinefra, M., D’amico, M., Mazzoni, E., Marino, A., Sponziello, F., et al. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.648925 · Cited by 9
Platin-basierte Therapie beim dreifach negativen Mammakarzinom
Eckstein, N., & Haas, B. (2012) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0031-1298891 · Cited by 9
Emerging drugs in metastatic breast cancer: an update
Arslan, Ç., Altundağ, K., & Dızdar, Ö. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.640672 · Cited by 9
Lovato, A., Panasci, L., & Witcher, M. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00202 · Cited by 9
Khalaf, D. J., Hilton, J. F., Clemons, M. J., Azoulay, L., Yin, H., Vandermeer, L., Dent, S. F., Hopkins, S. P., & Bouganim, N. (2014) · Oncology Letters · doi:10.3892/ol.2014.1782 · Cited by 9
Carey, L., Viale, G., Ellis, P., Abramowicz, M., & Piccart, M. J. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2011.217 · Cited by 9
Targeting the subtypes of breast cancer: rethinking investigational drugs
Curigliano, G., Locatelli, M., Fumagalli, L. A. M., Brollo, J., Munzone, E., Nolè, F., Criscitiello, C., & Goldhirsch, A. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.651456 · Cited by 8
Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer
Garber, H. R., & Litton, J. K. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000516 · Cited by 8
Triple Negative Breast Cancer Pathologic Diagnosis and Current Chemotherapy Treatment Options
Rapoport, B. L., Nayler, S., Demetriou, G. S., Moodley, S. D., & Benn, C. (2014) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2014.10.1.25 · Cited by 8
Forootan, S. S., Butler, J. M., Gardener, D., BAIRD, A. E., Dodson, A. R., Darby, A. C., Kenny, J. G., Hall, N., Cossins, A. R., Foster, C. S., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3222 · Cited by 8
Translationale Forschung und Diagnostik beim Mammakarzinom
Kreipe, H. H. (2012) · Der Pathologe · doi:10.1007/s00292-012-1645-1 · Cited by 8
Discussion of PARP Inhibitors in Cancer Therapy
Wielgos, M. E., & Yang, E. S.-H. (2013) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.13.53 · Cited by 8
Valentí, V., Jiménez‐Fonseca, P., Msaouel, P., Salazar, R., & Carmona‐Bayonas, A. (2021) · Cancer Investigation · doi:10.1080/07357907.2021.2020281 · Cited by 8
PARP inhibitors: current status and implications for anticancer therapeutics
Usmani, H., Hussain, S. A., & Sheikh, A. (2013) · Infectious Agents and Cancer · doi:10.1186/1750-9378-8-46 · Cited by 7
A Comprehensive Approach to the Identification and Management of the BRCA Patient
Garcia, C., & Powell, C. B. (2015) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000156 · Cited by 7
PARP Inhibitors in Ovarian Cancer
Staples, J. N., & Goodm, A. (2013) · InTech eBooks · doi:10.5772/52888 · Cited by 7
Strategies for targeting the DNA damage response for cancer therapeutics
Zhang, D., Wang, H., Brinkman, K. L., Han, S.-X., & Xu, B. (2012) · 癌症:英文版 · doi:10.5732/cjc.012.10087 · Cited by 7
Triple‐negative breast cancer: multipronged approach, single‐arm pilot phase II study
Recchia, F., Candeloro, G., Desideri, G., Necozione, S., Recchia, C. O. C., Cirulli, V., & Rea, S. (2012) · Cancer Medicine · doi:10.1002/cam4.3 · Cited by 7
Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer
Oh, S. Y., Rahman, S., & Sparano, J. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1876662 · Cited by 7
Liang, H., & Tan, A. R. (2011) · Current Breast Cancer Reports · doi:10.1007/s12609-010-0036-y · Cited by 7
Cant, A. A., Champion, S., Bhalla, R., Pimlott, S. L., & Sutherland, A. J. (2013) · Angewandte Chemie · doi:10.1002/ange.201302800 · Cited by 7
Pala, E. E., Bayol, Ü., Keskin, E. U., Özgüzer, A., Küçük, Ü., Ozer, O., & Koç, A. (2015) · Pathology & Oncology Research · doi:10.1007/s12253-015-9956-1 · Cited by 7
Bae, S. Y., Jung, S. P., Lee, S. K., Yu, J., Lee, J. E., Kim, S. W., & Nam, S. J. (2018) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2018.07.003 · Cited by 7
Purwanto, I., Dwiprahasto, I., Aryandono, T., & Mubarika, S. (2020) · Journal of the Medical Sciences (Berkala Ilmu Kedokteran) · doi:10.19106/jmedsci005201202009 · Cited by 7
Un trio de choc pour pallier la chimiorésistance des cancers : c-MYC, PARP1, BIN1
Pyndiah, S., & Sakamuro, D. (2013) · médecine/sciences · doi:10.1051/medsci/2013292006 · Cited by 7
Costanzo, M., Baryshnikova, A., VanderSluis, B., Andrews, B., Myers, C. L., & Boone, C. M. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-385944-0.00006-x · Cited by 8
Yan, Y., Ren, L., Liu, Y., & Liu, L. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.763281 · Cited by 6
A Highly Potent Os@Au‐TPA Coordination Structure‐Based Sonosensitizer for Tumor Sono‐Immunotherapies
Xie, P., Rong, X., Qin, X., Li, M., Zuo, Y., Liu, B., Cao, S., Yang, J., & Qiu, L. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202412564 · Cited by 6
Fu, S., Zou, P., Fang, Z., Zhou, X., Chen, J., Gong, C., Li, Q., Lin, B., Qiu, C., Lang, J., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13579-1 · Cited by 6
A review of iniparib in ovarian cancer
Wilkinson‐Ryan, I., & Mutch, D. G. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.772135 · Cited by 6
A Dickens Tale of the Treatment of Advanced Breast Cancer: The Past, the Present, and the Future
Sledge, G. W., Cardoso, F., Winer, E. P., & Piccart, M. J. (2012) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2012.32.306 · Cited by 6
Ro, E. J., Ryu, S.-H., Park, E., Ryu, J., Byun, S. J., Heo, S., Kim, K. H., Baek, I., Son, B. H., & Lee, S.-W. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05732-0 · Cited by 6
Advanced breast cancer metastasized in the brain: treatment standards and innovations
Klaas, E., Sung, E., Azizi, E., Martinez, M., Barpujari, A., Roberts, J., & Lucke-Wold, B. P. (2023) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.125 · Cited by 6
Timing Is Everything: Brca2 and p53 Mutations in Pancreatic Cancer
Morton, J. P., Steele, C. W., & Sansom, O. J. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.026 · Cited by 6
Advances in the approach to novel drug clinical development for breast cancer
Ferrario, C., & Batist, G. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.911282 · Cited by 6
Yi, C., Zhang, X., Chen, X., Huang, B., Song, J. K., Ma, M., Yuan, X., & Zhang, C. (2022) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320221103195 · Cited by 6
Lee, A., Go, S., Lee, W. S., Lee, U. S., Kim, M. J., Kang, M. H., Lee, G., Kim, H., Kang, J. H., Jeon, K. N., et al. (2015) · Tumori Journal · doi:10.5301/tj.5000198 · Cited by 6
Tumeurs localisées du sein triple négatives en 2016 : définitions et prise en charge
Portha, H., Jankowski, C., Cortet, M., Desmoulins, I., Martin, E., Lorgis, V., Arnould, L., & Coutant, C. (2016) · Gynécologie Obstétrique & Fertilité · doi:10.1016/j.gyobfe.2016.06.014 · Cited by 6
Thomssen, C., & Wand, D. (2012) · Der Onkologe · doi:10.1007/s00761-011-2095-8 · Cited by 6
Fan, P., & Wu, J. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105014 · Cited by 5
Metadata
- Authors
- O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C.
- Affiliations
- Texas Oncology (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-01-20
- Volume
- 364
- Issue
- 3
- Pages
- 205-214
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2111429259
- Cited by
- 817
- References
- 32
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 6 · 2023: 22 · 2022: 23 · 2021: 30 · 2020: 27 · 2019: 30 · 2018: 47 · 2017: 52 · 2016: 42 · 2015: 72 · 2014: 90 · 2013: 94 · 2012: 133
- FWCI
- 70.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- metastatic triple-negative breast cancer, PARP inhibition, gemcitabine, carboplatin, combination chemotherapy, DNA repair deficiency, clinical benefit, progression-free survival, overall survival, adverse events, neutropenia, thrombocytopenia, drug safety and efficacy
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Gemcitabine, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Breast Neoplasms, Deoxycytidine, Female, Humans, Neoplasm Metastasis, Survival Analysis, Carboplatin, Cross-Over Studies, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.